A recent trial reveals cemiplimab significantly reduces recurrence in high-risk cutaneous squamous cell carcinoma, setting a new standard for adjuvant treatment.
Danny Rischin, MD, MBBS, FRACP
Advertisement
Professor Danny Rischin is the director of Medical Oncology at the Peter MacCallum Cancer Centre.
Articles by Danny Rischin, MD, MBBS, FRACP
Danny Rischin, MD, MBBS, FRACP, discussed the results from a phase II trial looking at cemiplimab (Libtayo) in patients with advanced or recurrent cervical cancer.
Danny Rischin, MD, MBBS, FRACP, shares his insights on cemiplimab as a treatment for patients with metastatic cutaneous squamous cell carcinoma.
Danny Rischin, MD, MBBS, FRACP, discusses an ongoing phase III trial for patients with metastatic cutaneous squamous cell carcinoma or recurrent disease after progressing on frontline chemotherapy.
Advertisement
Latest Updated Articles
Phase III Trial for Patients With mCSCC Who Progress After First-line ChemotherapyPublished: November 19th 2018 | Updated:
Benefit With Cemiplimab in Patients With mCSCCPublished: December 18th 2018 | Updated:
Findings for Cemiplimab in Advanced or Recurrent Cervical CancerPublished: January 4th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
